InspireMD (NSPR) Set to Announce Earnings on Tuesday

InspireMD (NYSE:NSPR) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter.

InspireMD (NYSE:NSPR) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The business had revenue of $1.74 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative return on equity of 62.02% and a negative net margin of 388.67%. During the same period in the prior year, the firm earned ($0.24) EPS. On average, analysts expect InspireMD to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

InspireMD Stock Down 0.4 %

Shares of NYSE:NSPR traded down $0.01 on Tuesday, reaching $2.46. 13,316 shares of the company’s stock were exchanged, compared to its average volume of 23,933. The business’s 50-day moving average is $2.65 and its two-hundred day moving average is $2.56. InspireMD has a fifty-two week low of $1.81 and a fifty-two week high of $3.48. The firm has a market capitalization of $61.33 million, a price-to-earnings ratio of -3.34 and a beta of 0.93.

Analyst Ratings Changes

A number of brokerages have commented on NSPR. StockNews.com started coverage on InspireMD in a research note on Saturday. They issued a “sell” rating for the company. Piper Sandler restated an “overweight” rating and set a $4.50 price objective on shares of InspireMD in a research report on Tuesday, September 17th.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.